Special Populations

What is Evusheld?

AstraZeneca’s Evusheld is a therapeutic treatment option for certain individuals to help protect them from COVID-19 infection. The U.S. Food and Drug Administration recently issued an emergency use authorization (EUA) for Evusheld for the pre-exposure prevention of COVID-19 in certain adults and pediatric individuals (12 years of age and older weighing at least 88 pounds). Evusheld is not a substitute for the COVID-19 vaccine and is only authorized for individuals who are not currently infected with COVID-19 and who have not recently been exposed to an individual infected with the virus. The authorization also requires that individuals either have:

• Moderate to severely compromised immune systems due to a medical condition or due to taking immunosuppressive medications or treatments, such as receiving a transplant, active chemotherapy, etc., and may not mount an adequate immune response to COVID-19 vaccination (examples of such medical conditions or treatments can be found in the fact sheet for health care providers) OR;
• History of severe adverse reactions to a COVID-19 vaccine and/or component(s) of those vaccines, therefore vaccination with an available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended.

If you think you may qualify for this treatment, please consult with your physician treating your immunocompromising medical condition. Supplies of this treatment are extremely limited in the state and only available at certain locations. This treatment option requires a physician’s order is only available to those to meet the above criteria.